Isoliquiritigenin inhibits the proliferation, apoptosis and migration of osteosarcoma cells

Li,Chengjun; Zhou,Xing; Sun,Chang; Liu,Xiaozhou; Shi,Xin; Wu,Sujia

doi:10.3892/or.2019.6998

Isoliquiritigenin inhibits the proliferation, apoptosis and migration of osteosarcoma cells

Authors:
- Chengjun Li
- Xing Zhou
- Chang Sun
- Xiaozhou Liu
- Xin Shi
- Sujia Wu
View Affiliations

Affiliations: Department of Orthopedics, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, P.R. China
Published online on: February 4, 2019 https://doi.org/10.3892/or.2019.6998
Pages: 2502-2510

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The overall survival rate of patients with osteosarcoma has remained unchanged for the last several decades. Therefore, novel drugs for osteosarcoma treatment are required. Isoliquiritigenin (ISL), a natural compound, has been demonstrated to inhibit the growth of various tumors. However, it is unclear whether ISL is able to inhibit the growth of osteosarcoma. In the present study, it was identified that ISL was able to inhibit the growth of the osteosarcoma cell line Saos‑2 cells in vitro and in xenograft tumors primarily by attenuating tumor cell proliferation and, cell migration and promoting tumor cell apoptosis. Decreased tumor cell proliferation induced by ISL was associated with downregulation of cyclin D1 and upregulation of p53, p21 and p27. Increased tumor cell apoptosis triggered by ISL was associated with downregulation of apoptosis regulator Bcl‑2, upregulation of apoptosis regulator Bax and damaged mitochondrial function evidenced by a low level of ATP‑synthesis. In addition, ISL was able to inhibit the migratory capacity of Saos‑2 cells by modulating the expression of matrix metalloproteinase (MMP)2 and MMP9. Mechanistic analysis revealed that the tumor growth‑inhibitory effect of ISL may depend on the action of ISL on the phosphorylation of PI3K and AKT. However, it remains to be investigated whether the inhibitory effect of ISL on the migration of Saos‑2 cells was associated with downregulated PI3K/AKT signaling. Overall, the present study provided evidence for the potential use of ISL against osteosarcoma.

View Figures

View References

1	Zambo I and Vesely K: WHO classification of tumours of soft tissue and bone 2013: The main changes compared to the 3rd edition. Cesk Patol. 50:64–70. 2014.(In Czech). PubMed/NCBI
2	Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 118:5888–5893. 2012. View Article : Google Scholar : PubMed/NCBI
3	Eilber FR and Rosen G: Adjuvant chemotherapy for osteosarcoma. Semin Oncol. 16:312–322. 1989.PubMed/NCBI
4	Chin YW, Jung HA, Liu Y, Su BN, Castoro JA, Keller WJ, Pereira MA and Kinghorn AD: Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra). J Agric Food Chem. 55:4691–4697. 2007. View Article : Google Scholar : PubMed/NCBI
5	Peng F, Du Q, Peng C, Wang N, Tang H, Xie X, Shen J and Chen J: A review: The pharmacology of isoliquiritigenin. Phytother Res. 29:969–977. 2015. View Article : Google Scholar : PubMed/NCBI
6	Asl MN and Hosseinzadeh H: Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 22:709–724. 2008. View Article : Google Scholar : PubMed/NCBI
7	Lin Y, Sun H, Dang Y and Li Z: Isoliquiritigenin inhibits the proliferation and induces the differentiation of human glioma stem cells. Oncol Rep. 39:687–694. 2018.PubMed/NCBI
8	Chen HY, Huang TC, Shieh TM, Wu CH, Lin LC and Hsia SM: Isoliquiritigenin induces autophagy and inhibits ovarian cancer cell growth. Int J Mol Sci. 18(pii): E20252017. View Article : Google Scholar : PubMed/NCBI
9	Hsu YL, Kuo PL, Lin LT and Lin CC: Isoliquiritigenin inhibits cell proliferation and induces apoptosis in human hepatoma cells. Planta Med. 71:130–134. 2005. View Article : Google Scholar : PubMed/NCBI
10	Wang Z, Wang N, Han S, Wang D, Mo S, Yu L, Huang H, Tsui K, Shen J and Chen J: Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One. 8:e685662013. View Article : Google Scholar : PubMed/NCBI
11	Jung JI, Chung E, Seon MR, Shin HK, Kim EJ, Lim SS, Chung WY, Park KK and Park JH: Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. Biofactors. 28:159–168. 2006. View Article : Google Scholar : PubMed/NCBI
12	Li Y, Zhao H, Wang Y, Zheng H, Yu W, Chai H, Zhang J, Falck JR, Guo AM, Yue J, et al: Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of PI3K/Akt in human breast cancer. Toxicol Appl Pharmacol. 272:37–48. 2013. View Article : Google Scholar : PubMed/NCBI
13	Wang KL, Hsia SM, Chan CJ, Chang FY, Huang CY, Bau DT and Wang PS: Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells. Expert Opin Ther Targets. 17:337–349. 2013. View Article : Google Scholar : PubMed/NCBI
14	Zhu J, Sun Y, Lu Y, Jiang X, Ma B, Yu L, Zhang J, Dong X and Zhang Q: Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nuclear translocation via regulating PI3K/Akt pathway. Cell Death Dis. 9:7082018. View Article : Google Scholar : PubMed/NCBI
15	Angulo P, Kaushik G, Subramaniam D, Dandawate P, Neville K, Chastain K and Anant S: Natural compounds targeting major cell signaling pathways: A novel paradigm for osteosarcoma therapy. J Hematol Oncol. 10:102017. View Article : Google Scholar : PubMed/NCBI
16	Zhang J, Yu XH, Yan YG, Wang C and Wang WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta. 444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
17	Wu CH, Chen HY, Wang CW, Shieh TM, Huang TC, Lin LC, Wang KL and Hsia SM: Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice. Oncotarget. 7:73432–73447. 2016.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ingham M and Schwartz GK: Cell-cycle therapeutics come of age. J Clin Oncol. 35:2949–2959. 2017. View Article : Google Scholar : PubMed/NCBI
20	Akin S, Babacan T, Sarici F and Altundag K: A novel targeted therapy in breast cancer: Cyclin dependent kinase inhibitors. J Buon. 19:42–46. 2014.PubMed/NCBI
21	Wang Y, Ma J, Yan X, Chen X, Si L, Liu Y, Han J, Hao W and Zheng Q: Isoliquiritigenin inhibits proliferation and induces apoptosis via alleviating hypoxia and reducing glycolysis in mouse melanoma B16F10 cells. Recent Pat Anticancer Drug Discov. 11:215–227. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zhang X, Yeung ED, Wang J, Panzhinskiy EE, Tong C, Li W and Li J: Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells. Clin Exp Pharmacol Physiol. 37:841–847. 2010.PubMed/NCBI
23	Maggiolini M, Statti G, Vivacqua A, Gabriele S, Rago V, Loizzo M, Menichini F and Amdò S: Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J Steroid Biochem Mol Biol. 82:315–322. 2002. View Article : Google Scholar : PubMed/NCBI
24	Li ZX, Li J, Li Y, You K, Xu H and Wang J: Novel insights into the apoptosis mechanism of DNA topoisomerase I inhibitor isoliquiritigenin on HCC tumor cell. Biochem Biophys Res Commun. 464:548–553. 2015. View Article : Google Scholar : PubMed/NCBI
25	Jung SK, Lee MH, Lim DY, Kim JE, Singh P, Lee SY, Jeong CH, Lim TG, Chen H, Chi YI, et al: Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR. J Biol Chem. 289:35839–35848. 2014. View Article : Google Scholar : PubMed/NCBI
26	Hirchaud F, Hermetet F, Ablise M, Fauconnet S, Vuitton DA, Prétet JL and Mougin C: Isoliquiritigenin induces caspase-dependent apoptosis via downregulation of HPV16 E6 expression in cervical cancer Ca Ski cells. Planta Med. 79:1628–1635. 2013. View Article : Google Scholar : PubMed/NCBI
27	Chen G, Hu X, Zhang W, Xu N, Wang FQ, Jia J, Zhang WF, Sun ZJ and Zhao YF: Mammalian target of rapamycin regulates isoliquiritigenin-induced autophagic and apoptotic cell death in adenoid cystic carcinoma cells. Apoptosis. 17:90–101. 2012. View Article : Google Scholar : PubMed/NCBI
28	Yuan X, Zhang B, Gan L, Wang ZH, Yu BC, Liu LL, Zheng QS and Wang ZP: Involvement of the mitochondrion-dependent and the endoplasmic reticulum stress-signaling pathways in isoliquiritigenin-induced apoptosis of HeLa cell. Biomed Environ Sci. 26:268–276. 2013.PubMed/NCBI
29	Jung JI, Lim SS, Choi HJ, Cho HJ, Shin HK, Kim EJ, Chung WY, Park KK and Park JH: Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J Nutr Biochem. 17:689–696. 2006. View Article : Google Scholar : PubMed/NCBI
30	Yang HH, Zhang C, Lai SH, Zeng CC, Liu YJ and Wang XZ: Isoliquiritigenin induces cytotoxicity in PC-12 cells in vitro. Appl Biochem Biotechnol. 183:1173–1190. 2017. View Article : Google Scholar : PubMed/NCBI
31	Kale J, Osterlund EJ and Andrews DW: BCL-2 family proteins: Changing partners in the dance towards death. Cell Death Differ. 25:65–80. 2018. View Article : Google Scholar : PubMed/NCBI
32	Maes ME, Schlamp CL and Nickells RW: BAX to basics: How the BCL2 gene family controls the death of retinal ganglion cells. Prog Retin Eye Res. 57:1–25. 2017. View Article : Google Scholar : PubMed/NCBI
33	Strasser A and Vaux DL: Viewing BCL2 and cell death control from an evolutionary perspective. Cell Death Differ. 25:13–20. 2018. View Article : Google Scholar : PubMed/NCBI
34	Hsu YL, Kuo PL and Lin CC: Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. Life Sci. 77:279–292. 2005. View Article : Google Scholar : PubMed/NCBI
35	Kwon GT, Cho HJ, Chung WY, Park KK, Moon A and Park JH: Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: Possible mediation by decreased JNK/AP-1 signaling. J Nutr Biochem. 20:663–676. 2009. View Article : Google Scholar : PubMed/NCBI
36	Chien MH, Lin CW, Cheng CW, Wen YC and Yang SF: Matrix metalloproteinase-2 as a target for head and neck cancer therapy. Expert Opin Ther Targets. 17:203–216. 2013. View Article : Google Scholar : PubMed/NCBI
37	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
38	Yang JS, Lin CW, Su SC and Yang SF: Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol. 12:191–200. 2016. View Article : Google Scholar : PubMed/NCBI
39	Lan H, Hong W, Fan P, Qian D, Zhu J and Bai B: Quercetin inhibits cell migration and invasion in human osteosarcoma cells. Cell Physiol Biochem. 43:553–567. 2017. View Article : Google Scholar : PubMed/NCBI
40	Kunz P, Sahr H, Lehner B, Fischer C, Seebach E and Fellenberg J: Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma. BMC Cancer. 16:2232016. View Article : Google Scholar : PubMed/NCBI
41	Yang Z, Zeng B, Pan Y, Huang P and Wang C: Autophagy participates in isoliquiritigenin-induced melanin degradation in human epidermal keratinocytes through PI3K/AKT/mTOR signaling. Biomed Pharmacother. 97:248–254. 2018. View Article : Google Scholar : PubMed/NCBI
42	Chen T, Deng S and Lin R: The inhibitory effect of Isoliquiritigenin on the proliferation of human arterial smooth muscle cell. BMC Pharmacol Toxicol. 18:572017. View Article : Google Scholar : PubMed/NCBI